Corvus Pharmaceuticals Announces Participation in Upcoming Investor Conferences

Rhea-AI Summary

Corvus Pharmaceuticals, a clinical-stage biopharmaceutical company (NASDAQ: CRVS), announced participation in two investor conferences in September 2021. The first event, the H.C. Wainwright Annual Global Investment Conference, is set for September 13-15, where CEO Richard A. Miller will offer a pre-recorded presentation available starting September 13 at 7:00 am ET. The second event, the Cantor Virtual Global Healthcare Conference, runs from September 27-30, with Dr. Miller presenting on September 29 from 3:20-3:50 pm ET. Webcast replays will be accessible for 90 days post-event.

BURLINGAME, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the Company’s management will participate in two upcoming investor conferences in September:

• The first conference is the H.C. Wainwright Annual Global Investment Conference, which is taking place September 13-15, 2021. The Company will conduct one-on-one meetings with investors at this conference and a pre-recorded corporate overview presentation by Richard A. Miller, M.D., president and chief executive officer of Corvus, will be available to play on-demand starting at 7:00 am ET on September 13. Attendees can register to view the webcast here.
  
  
• The second conference is the Cantor Virtual Global Healthcare Conference, which is taking place September 27-30, 2021. The Company will conduct one-on-one meetings with investors at this conference and a virtual corporate overview presentation will be conducted by Dr. Miller at 3:20-3:50 pm ET on September 29. Attendees can register for the virtual presentation here.
  

Attendees can also access the webcast of the presentations noted above via the investor relations section of the Corvus website and replays will be available for 90 days following the events.

About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company. Corvus’ lead product candidate is mupadolimab (CPI-006), a humanized monoclonal antibody directed against CD73 that has exhibited immunomodulatory activity and is currently being evaluated in Phase 1b/2 clinical trials in patients with either head and neck cancers or lung cancers. The Company’s second clinical program, CPI-818, is an investigational, oral, small molecule drug that selectively inhibited ITK in preclinical studies, and is in a multicenter Phase 1/1b clinical trial in patients with several types of T-cell lymphomas. Its third clinical program, ciforadenant (CPI-444), is an oral, small molecule inhibitor of the A2A receptor. For more information, visit www.corvuspharma.com.

INVESTOR CONTACT:
Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
+1-650-900-4522
llea@corvuspharma.com 

MEDIA CONTACT:
Sheryl Seapy
Real Chemistry
+1-949-903-4750
sseapy@realchemistry.com 

FAQ

What are the dates of the Corvus Pharmaceuticals investor conferences in September 2021?

The investor conferences for Corvus Pharmaceuticals are scheduled for September 13-15, 2021, and September 27-30, 2021.

Who will present at the H.C. Wainwright Annual Global Investment Conference?

Richard A. Miller, M.D., president and CEO of Corvus Pharmaceuticals, will present at the H.C. Wainwright Annual Global Investment Conference.

When will the webcasts of the Corvus Pharmaceuticals presentations be available?

Webcasts of the presentations will be available starting September 13, 2021, and replays will be accessible for 90 days after the events.

What is the stock symbol for Corvus Pharmaceuticals?

The stock symbol for Corvus Pharmaceuticals is CRVS.

What is the focus of Corvus Pharmaceuticals' lead product candidate?

Corvus Pharmaceuticals' lead product candidate, mupadolimab (CPI-006), targets CD73 and is being evaluated for head and neck cancers and lung cancers.